Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia.

Leukemia research - 1 Feb 2018

Strickland Stephen A, Shaver Aaron C, Byrne Michael, Daber Robert D, Ferrell P Brent, Head David R, Mohan Sanjay R, Mosse Claudio A, Moyo Tamara K, Stricker Thomas P, Vnencak-Jones Cindy, Savona Michael R, Seegmiller Adam C

Abstract excerpt

The National Comprehensive Cancer Network (NCCN) defines the following types of acute myeloid leukemia (AML) as favorable-risk: acute promyelocytic leukemia with t(15;17) (APL); AML with core-binding factor (CBF) rearrangements, including t(8;21) and inv(16) or t(16;16) without mutations in KIT (CBF-KITwt); and AML with normal cytogenetics and mutations in NPM1 (NPM1mut); or biallelic mutations in CEBPA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CCAAT-Enhancer-Binding Proteins
Share to Core Binding Factors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Order

Share to Kaplan-Meier Estimate

Share to Karyotyping

Share to Leukemia, Myeloid, Acute

Share to Nucleophosmin

Share to Proto-Oncogene Proteins c-kit

Source

Open in PubMed Open full text

Identifiers

PMID: 29310020
DOI: 10.1016/j.leukres.2017.12.012
PMCID: PMC5856485

Genes

FLT3
KIT
NPM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia.PMID 29310020Read ↗

Recent progress in AML with recurrent genetic abnormalities.Semantic proximity Read ↗

Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk NPM1-mutated AML.Semantic proximity Read ↗

Advances in therapeutic options for newly diagnosed, high-risk AML patientsSemantic proximity Read ↗

Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years.Semantic proximity Read ↗

Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia.Semantic proximity Read ↗

Core Binding Factor AML Beyond Favorable Risk: Molecular Heterogeneity, MRD Dynamics, and Implications for Clinical Decision-MakingSemantic proximity Read ↗

Management of patients with cytogenetically normal acute myeloid leukemia who have neither favorable nor unfavorable markers.Semantic proximity Read ↗

Identification of molecular and cytogenetic risk factors for unfavorable core-binding factor-positive adult AML with post-remission treatment outcome analysis including transplantation.Semantic proximity Read ↗

Blast phenotype and comutations in acute myeloid leukemia with mutated NPM1 influence disease biology and outcome.Semantic proximity Read ↗

Cytogenetic abnormalities in NPM1-mutated acute myeloid leukemia.Semantic proximity Read ↗

Mutational landscape of AML with normal cytogenetics: biological and clinical implications.Semantic proximity Read ↗

Acute myeloid leukemia: 2013 update on risk‐stratification and managementSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.